Knight Therapeutics Secures Approval for TAVALISSE® in Mexico
Knight Therapeutics Inc. (TSX: GUD), a leading specialty pharmaceutical company based in Montreal, has announced significant news regarding its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. The firm recently received regulatory approval from COFEPRIS for its innovative treatment, TAVALISSE® (fostamatinib disodium hexahydrate), specifically aimed at adult patients suffering from chronic immune thrombocytopenia (ITP) who have not responded satisfactorily to previous therapies.
Understanding the Impact of TAVALISSE® on ITP
Dr. Luis Antonio Meillón García, a noted hematologist, commented on the challenges of treating chronic ITP, noting the unpredictable patient responses to existing therapies. The approval of TAVALISSE® offers a crucial new option for physicians, expanding their arsenal against this complex condition. This treatment features a unique mechanism of action that sets it apart from traditional therapies.
The Clinical Journey of TAVALISSE®
Previously, Knight Therapeutics entered into an agreement with Rigel Pharmaceuticals, Inc. to secure exclusive commercialization rights for fostamatinib in Latin America back in 2022. This agreement opens the door for innovative treatment options in a region that has been underserved in terms of advanced therapeutic developments.
TAVALISSE® is an oral medication categorized as a spleen tyrosine kinase (SYK) inhibitor. While already available in the United States, under the same brand, and in Europe as TAVLESSE®, its introduction in Mexico marks a significant milestone for patient care in Latin America. The medication will be provided in both 100 mg and 150 mg tablet forms.
A Commitment to Enhancing Patient Outcomes
Samira Sakhia, President and CEO of Knight Therapeutics, expressed enthusiasm regarding the approval, highlighting its importance for patients with chronic ITP. She stated that the launch of TAVALISSE® in Mexico is expected in the first half of 2026, thus promising a vital new option for those in need.
More About ITP and Treatment Options
Chronic ITP poses significant health risks as the immune system erroneously targets and destroys platelets, crucial for clotting and healing. Patients may experience excessive bruising and bleeding, along with increased risks of severe health complications. Existing therapies include steroids and platelet production boosters like thrombopoietin receptor agonists, but many patients do not respond effectively to these treatments. This reality underscores the urgent demand for additional therapeutic options to improve patient outcomes.
Founded on Innovation and Expertise
Headquartered in Montreal, Knight Therapeutics Inc. has built its reputation around acquiring and commercializing innovative pharma products for Canada and Latin America. Operating through its subsidiaries—United Medical, Biotoscana Farma, and Laboratorio LKM—the company aims to revolutionize patient care across these regions. Knight Therapeutics Inc.'s stock is actively traded on the TSX under the ticker GUD.
Frequently Asked Questions
What is TAVALISSE® approved for?
TAVALISSE® is approved for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have not had sufficient response to prior treatments.
When will TAVALISSE® be launched in Mexico?
TAVALISSE® is expected to be launched in Mexico in the first half of 2026.
What makes TAVALISSE® different from other ITP treatments?
TAVALISSE® is a spleen tyrosine kinase (SYK) inhibitor, representing an innovative mechanism of action compared to traditional therapies.
Who are the key executives at Knight Therapeutics?
The key executives include Samira Sakhia, President & CEO, and Arvind Utchanah, Chief Financial Officer.
Where can I find more information about Knight Therapeutics?
For more information, visit Knight Therapeutics' website at www.knighttx.com.
